INDV Q4 2024 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$299M+2.0% YoY

Gross Profit

$276M92.3% margin

Operating Income

$96M32.1% margin

Net Income

$59M19.7% margin

EPS (Diluted)

$0.45

QoQ Revenue Growth

-2.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.7B

Stockholders' Equity

-$348M

Cash & Equivalents

$319M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$299M	$293M	+2.0%
Gross Profit	$276M	$242M	+14.0%
Operating Income	$96M	$61M	+57.4%
Net Income	$59M	$54M	+9.3%